BlackRock Raises Stake in COPASA MG to 5.017%
Bitget2026/11/06 22:27- BlackRock increased its stake in COPASA MG to 19,077,303 ordinary shares, or approximately 5.02%, as of Nov. 4, 2026.
- Its holdings also included 76,372 cash-settled financial derivative instruments referenced to ordinary shares, representing approximately 0.02%.
- The investment manager notified the company on Nov. 6, 2026, acting on behalf of some clients.
- The holdings are solely for investment, with no intention to change control or management structure; no voting or securities-trading agreements were entered.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
CleanSpark presents fully funded Sandersville project in investor presentation
Crypto prices
More
